14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today AKTX ranks #13962 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

Akari Therapeutics Plc Stock Forecast NASDAQ:AKTX

$1.43 (-1.38%)

Volume: 153k

Closed: Jan 21, 2022

Hollow Logo Score: -3.185

Akari Therapeutics Plc Stock Forecast

$1.43 (-1.38%)

Volume: 153k

Closed: Jan 21, 2022

Score Hollow Logo -3.185

Akari Therapeutics Plc Company Profile

24 West 40th Street

New York NY 10018



Industry: Biotechnology

Sector: Healthcare

Akari Therapeutics Plc


Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat rare and orphan autoimmune and inflammatory diseases. Its lead drug candidate is Coversin, a second-generation C5 complement inhibitor that is in Phase Ib clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, and atypical hemolytic uremic syndrome. The company is based in New York, New York. Akari Therapeutics, Plc is a subsidiary of RPC Pharma Limited.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE